Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors
Status:
Recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The is a phase II, single arm, open-label, multi-site trial studying the combination of
cryoablation therapy and dual checkpoint inhibition with nivolumab (anti-PD-1) and ipilimumab
(anti-CTLA-4) given at the recommended phase 2 dose (RP2D) in pediatric and young adult
patients with relapsed or refractory solid tumors.